Arrowstreet Capital’s Novavax NVAX Stock Holding History

Arrowstreet Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-127,609	Closed	-$6.56M	–	1409
2022 Q2	$6.56M	Buy	+127,609	New	+$6.61M	0.01%	561
2021 Q1	–	Sell	-2,700	Closed	-$301K	–	2436
2020 Q4	$301K	Buy	+2,700	New	+$287K	﹤0.01%	2119
2015 Q3	–	Sell	-2,720	Closed	-$606K	–	1451
2015 Q2	$606K	Buy	+2,720	New	+$478K	﹤0.01%	945
2014 Q2	–	Sell	-13,011	Closed	-$1.18M	–	1121
2014 Q1	$1.18M	Buy	+13,011	New	+$1.45M	0.01%	784

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Arrowstreet Capital's NVAX Position: Q3 2022 in Review

Arrowstreet Capital sold out of Novavax (NVAX) in Q3 2022, closing a stake of 127,609 shares — an estimated $6.56M sold.

Arrowstreet Capital first reported a position in NVAX in Q1 2014 and held it in 4 quarters. The position peaked at $6.56M in Q2 2022. 253 funds tracked by Wall St. Rank hold NVAX as of Q3 2022.

Arrowstreet Capital reported no remaining Novavax position as of Q3 2022 after selling out during the quarter.
Arrowstreet Capital sold 127,609 Novavax shares in Q3 2022, an estimated $6.56M.
Arrowstreet Capital first reported a position in Novavax in Q1 2014 and held it in 4 quarters.
Arrowstreet Capital's Novavax position peaked at $6.56M in Q2 2022.
253 funds tracked by Wall St. Rank held Novavax as of Q3 2022.

Based on Arrowstreet Capital's 13F filing for Q3 2022, filed 14 Nov 2022.